[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100630783":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":29,"centralContacts":34,"locations":43,"responsibleParty":60,"collaborators":25,"id":63,"slug":64,"hasResults":65,"nctId":66,"briefTitle":67,"officialTitle":68,"acronym":25,"eligibilityCriteria":69,"healthyVolunteers":65,"sex":70,"minAge":71,"maxAge":25,"enrollmentInfo":72,"targetDuration":25,"studyType":75,"phases":76,"briefSummary":78,"conditions":79,"keywords":82,"overallStatus":45,"whyStopped":25,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":94},{"fullName":5,"class":6},"Maimonides Medical Center","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Cabergoline","EXPERIMENTAL","Participants undergoing abortion or pregnancy loss between 12 and 18 weeks of gestation will receive a single 1 mg oral dose of Cabergoline approximately one hour after the procedure. Participants will complete baseline and follow-up surveys assessing breast symptoms, including breast engorgement, milk leakage, tenderness, and need for pain relief, at multiple time points through 14 days after the procedure. A subset of participants may also provide blood samples for measurement of serum prolactin levels.",[13],"Drug: Cabergoline",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Participants undergoing abortion or pregnancy loss between 12 and 18 weeks of gestation will receive a single oral dose of placebo approximately one hour after the procedure. Participants will complete baseline and follow-up surveys assessing breast symptoms, including breast engorgement, milk leakage, tenderness, and need for pain relief, at multiple time points through 14 days after the procedure. A subset of participants may also provide blood samples for measurement of serum prolactin levels.",[19],"Drug: Placebo",[21,26],{"type":22,"name":9,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Participants will receive a single oral dose of 1 mg of Cabergoline administered approximately one hour after completion of the abortion or pregnancy loss procedure. Cabergoline is a dopamine agonist that suppresses prolactin secretion and is used in this study to inhibit lactation and reduce breast symptoms.",[9],null,{"type":22,"name":15,"description":27,"armGroupLabels":28,"otherNames":25},"Participants will receive a single oral dose of a placebo tablet administered approximately one hour after completion of the abortion or pregnancy loss procedure. The placebo will be identical in appearance to the cabergoline tablet and contains no active medication",[15],[30],{"name":31,"affiliation":32,"role":33},"June Ng, MD","Maimonides Medical Canter","PRINCIPAL_INVESTIGATOR",[35,39],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},"CONTACT","718-283-7048","JuNg@maimo.org",{"name":40,"role":36,"phone":41,"phoneExt":25,"email":42},"Olivia Sher, MPH","718-283-7962","OSher@maimo.org",[44],{"facility":5,"status":45,"city":46,"state":47,"zip":48,"country":49,"countryCode":50,"cosmosGeoPoint":51,"geoPoint":56,"contacts":57},"RECRUITING","Brooklyn","New York","11219","United States","US",{"type":52,"coordinates":53},"Point",[54,55],-73.94958,40.6501,{"lat":55,"lon":54},[58,59],{"name":31,"role":36,"phone":37,"phoneExt":25,"email":38},{"name":31,"role":33,"phone":25,"phoneExt":25,"email":25},{"type":33,"investigatorFullName":61,"investigatorTitle":62,"investigatorAffiliation":5,"oldNameTitle":25,"oldOrganization":25},"June Ng","Attending Physician","100630783","phase-2-efficacy-of-cabergoline-in-inhibiting-lactation-and-alleviating-breast-symptoms-100630783",false,"NCT07492160","Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms","Efficacy of Cabergoline in Inhibiting Lactation and Alleviating Breast Symptoms After 12-18 Week Abortion or Pregnancy Loss: A Pilot and Randomized Controlled Trial","Inclusion Criteria:\n\n* Pregnant people aged 18 years or older\n* Gestational age between 12 and 18 weeks\n* Undergoing treatment for spontaneous or induced abortion at Maimonides Medical Center\n* Able to provide informed consent\n* Willing and able to complete study surveys\n\nExclusion Criteria:\n\n* Prior mastectomy\n* Currently breastfeeding\n* Current use of a dopamine agonist or dopamine antagonist medication\n* Known contraindication to Cabergoline according to the medication prescribing information","FEMALE","18 Years",{"count":73,"type":74},348,"ESTIMATED","INTERVENTIONAL",[77],"PHASE2","The goal of this clinical trial is to learn whether cabergoline can prevent lactation and reduce breast symptoms in pregnant people aged 18 years or older undergoing abortion or pregnancy loss between 12 and 18 weeks of gestation. The main questions it aims to answer are:\n\nDoes cabergoline decrease the proportion of participants who experience breast symptoms (including breast engorgement, milk leakage, tenderness, and need for pain relief) after abortion or pregnancy loss?\n\nDoes cabergoline reduce the severity of breast symptoms and associated bother compared with placebo?\n\nResearchers will compare participants receiving cabergoline to those receiving placebo to determine whether cabergoline reduces the frequency and severity of breast symptoms following abortion or pregnancy loss.\n\nParticipants will:\n\nComplete a baseline survey assessing breast symptoms prior to the abortion or pregnancy loss procedure\n\nReceive a single oral dose of either cabergoline (1 mg) or placebo approximately one hour after the procedure\n\nComplete follow-up surveys on days 2, 3, 4, 7, and 14 after the procedure to assess breast symptoms and related bother\n\nA subset of participants will provide blood samples at selected time points to measure serum prolactin levels",[80,81],"Pregnancy","Abortion",[83,84],"cabergoline","pregnancy","2026-03-19",{"date":87,"type":88},"2026-03-25","ACTUAL",{"date":90,"type":88},"2026-03-16",{"date":92,"type":74},"2028-04",{"name":5,"class":6},1]